本页面由Tiger Trade Technology Pte. Ltd.提供服务

Inozyme Pharma

4.00
0.0000
成交量:- -
成交额:583.41万
市值:2.60亿
市盈率:-2.38
高:4.00
开:4.00
低:4.00
收:4.00
52周最高:6.24
52周最低:0.7210
股本:6,491.57万
流通股本:3,014.82万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-1.6822
每股收益(LYR):-1.6243
净资产收益率:-141.69%
总资产收益率:-48.45%
市净率:8.17
市盈率(LYR):-2.46

数据加载中...

2024/11/05

重要事件披露

Form 8-K - Current report
2024/10/24

重要事件披露

Form 8-K - Current report
2024/10/08

重要事件披露

Form 8-K - Current report
2024/08/06

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/06

重要事件披露

Form 8-K - Current report
2024/08/06

重要事件披露

Form 8-K - Current report
2024/06/21

重要事件披露

Form 8-K - Current report
2024/05/07

重要事件披露

Form 8-K - Current report
2024/05/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/04/08

重要事件披露

Form 8-K - Current report
2024/03/12

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/12

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/12

重要事件披露

Form 8-K - Current report
2024/02/20

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals